Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

被引:84
作者
Wilcock, D. M. [1 ]
Jantzen, P. T. [1 ]
Li, Q. [1 ]
Morgan, D. [1 ]
Gordon, M. N. [1 ]
机构
[1] Univ S Florida, Coll Med, Alzheimers Res Lab, Dept Mol Pharmacol & Physiol,Sch Basic Biomed Sci, Tampa, FL 33612 USA
关键词
microglia; inflammation; cerebral amyloid angiopathy; immunotherapy; Alzheimer's disease;
D O I
10.1016/j.neuroscience.2006.10.020
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vaccination with A beta(1-42) and treatment with NCX2216, a novel nitric oxide releasing flurbiprofen derivative, have each been shown separately to reduce amyloid deposition in transgenic mice and have been suggested as potential therapies for Alzheimer's disease. In the current study we treated doubly transgenic amyloid precursor protein and presenilin-1 (APP+PS1) mice with A beta(1-42) vaccination, NCX-2216 or both drugs simultaneously for 9 months. We found that all treatments reduced amyloid deposition, both compact and diffuse, to the same extent while only vaccinated animals, with or without nonsteroidal anti-inflammatory drug (NSAID) treatment, showed increased microglial activation associated with the remaining amyloid deposits. We also found that active A beta vaccination resulted in significantly increased cerebral amyloid angiopathy and associated microhemorrhages, while NCX-2216 did not, in spite of similar reductions in parenchymal amyloid. Co-administration of NCX-2216 did not attenuate this effect of the vaccine. This is the first report showing that active immunization can result in increased vascular amyloid and microhemorrhage, as has been observed with passive immunization. Co-administration of an NSAID agent with A beta vaccination does not substantially modify the effects of A beta immunotherapy. The difference between these treatments with respect to vascular amyloid development may reflect the clearance-promoting actions of the vaccine as opposed to the prod uction-modifying effects proposed for flurbiprofen. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:950 / 960
页数:11
相关论文
共 42 条
[1]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[2]   Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms [J].
Attems, J .
ACTA NEUROPATHOLOGICA, 2005, 110 (04) :345-359
[3]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[4]   Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology [J].
Bard, F ;
Barbour, R ;
Cannon, C ;
Carretto, R ;
Fox, M ;
Games, D ;
Guido, T ;
Hoenow, K ;
Hu, K ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, C ;
Lee, M ;
Motter, R ;
Nguyen, M ;
Reed, A ;
Schenk, D ;
Tang, P ;
Vasquez, N ;
Seubert, P ;
Yednock, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :2023-2028
[5]   Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: Implications for chronic treatments of neurodegenerative diseases [J].
Bernardo, A ;
Gasparini, L ;
Ongini, E ;
Minghetti, L .
NEUROBIOLOGY OF DISEASE, 2006, 22 (01) :25-32
[6]   Immune responses against Aβ1-42 in HLA class II transgenic mice:: implications for Aβ1-42 immune-mediated therapies [J].
Das, P ;
Chapoval, S ;
Howard, V ;
David, CS ;
Golde, TE .
NEUROBIOLOGY OF AGING, 2003, 24 (07) :969-976
[7]   IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor [J].
Deane, R ;
Sagare, A ;
Hamm, K ;
Parisi, M ;
LaRue, B ;
Guo, HA ;
Wu, ZH ;
Holtzman, DM ;
Zlokovic, BV .
JOURNAL OF NEUROSCIENCE, 2005, 25 (50) :11495-11503
[8]   Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Dodart, JC ;
Paul, SM ;
Holtzman, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855
[9]   Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide [J].
Dickey, CA ;
Morgan, DG ;
Kudchodkar, S ;
Weiner, DB ;
Bai, Y ;
Cao, CH ;
Gordon, MN ;
Ugen, KE .
DNA AND CELL BIOLOGY, 2001, 20 (11) :723-729
[10]   Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1 [J].
Duff, K ;
Eckman, C ;
Zehr, C ;
Yu, X ;
Prada, CM ;
Pereztur, J ;
Hutton, M ;
Buee, L ;
Harigaya, Y ;
Yager, D ;
Morgan, D ;
Gordon, MN ;
Holcomb, L ;
Refolo, L ;
Zenk, B ;
Hardy, J ;
Younkin, S .
NATURE, 1996, 383 (6602) :710-713